AlphAIAlphAI — Financial news for AI agents
quiverquant.comNOV 32 min read$BNTX

BIONTECH SE ($BNTX) Releases Q3 2026 Earnings

BIONTECH SE ($BNTX) reported Q3 2026 earnings of $1.82 per share, exceeding estimates by $1.01, with revenue of $1.33 billion, surpassing expectations by $251.26 million. Insiders sold 706,209 shares, while hedge funds showed mixed activity. Analysts' price targets range from $96 to $135.

Original reporting
quiverquant.com
Published Nov 3, 2026, 12:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 1:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
BIONTECH SE ($BNTX) Releases Q3 2026 Earnings — source image
Source · quiverquant.com
Decision brief

The 30-second read

$BNTXBullishHigh
01

Why it matters

The earnings beat could drive short-term buying interest, especially in after-hours trading.

02

Market read

Earnings beat provides a fresh catalyst for BNTX traders.

03

What to watch

Potential regulatory or pipeline risks not addressed in the earnings release.

Relevance 8/10Novelty 8/10Timing: after-hours

Background

The article summarizes Biontech's Q3 2026 earnings and related insider/hedge fund activity.

Company-level read

Ticker impact

$BNTXBullishHigh confidence
Context

Biontech reported Q3 2026 earnings beating EPS and revenue estimates.

Expected impact

likely upward pressure as market prices in the earnings beat

Evidence & confidence

EPS of $1.82 vs $0.80 estimate and revenue $1.33B vs $1.08B estimate indicate strong performance.

Market effects

Sector

Biotech sector may see broader optimism from a major player beating expectations.

Regional

European and US biotech markets could see modest gains.

Global

Limited to biotech investors; no broad market impact.

Counterpoint

What could challenge this read

Some investors may question sustainability of growth given high expectations.

Key entities

  • company
    Biontech SE

    Biotech firm reporting earnings.

Read at source← All news

StoryBioNTech posts Q3 profit, raises FY revenue outlook as oncology pipeline advances

Also covered by

4 outlets

Related articles

NOV 3
$BNTXMedAI 8/10

BioNTech returns to profit in 3rd quarter, raises 2026 revenue outlook

BioNTech reported a Q3 net profit of €184.5M, reversing a year-earlier loss, and raised its 2026 revenue outlook to €1.7B-€1.9B. Revenue declined 15.1% YoY to €1.29B due to weaker COVID-19 vaccine demand. Lower legal expenses and increased R&D spending were key factors. The company's net loss widened to €1.17B for the first nine months of 2026.

aa.com.tr4 min
NOV 3
$BNTXHighAI 8/10

BioNTech Reports Third-Quarter Results, Advances Oncology Pipeline

BioNTech SE (BNTX) reported Q3 2026 revenue of €1.289 billion, down from €1.519 billion a year earlier, with net profit of €184.5 million. The company advanced its oncology pipeline, including data for pumitamig plus elfetabart drozuntecan in lung cancer and a Phase 3 trial for triple-negative breast cancer. Analysts have a mixed outlook on BNTX stock, with a Buy rating and $114.00 price target, while Spark's AI Analyst rates it as Neutral.

tipranks.com2 min